A detailed history of Envestnet Asset Management Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 28,171 shares of BEAM stock, worth $679,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,171
Previous 20,538 37.17%
Holding current value
$679,484
Previous $481,000 43.45%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$22.57 - $33.14 $172,276 - $252,957
7,633 Added 37.17%
28,171 $690,000
Q2 2024

Aug 08, 2024

SELL
$21.22 - $32.66 $33,994 - $52,321
-1,602 Reduced 7.24%
20,538 $481,000
Q1 2024

May 13, 2024

BUY
$23.46 - $45.07 $2,275 - $4,371
97 Added 0.44%
22,140 $731,000
Q4 2023

Feb 13, 2024

BUY
$17.69 - $30.76 $210,511 - $366,044
11,900 Added 117.32%
22,043 $600,000
Q3 2023

Nov 13, 2023

SELL
$23.01 - $32.46 $117,304 - $165,481
-5,098 Reduced 33.45%
10,143 $243,000
Q2 2023

Aug 04, 2023

BUY
$29.32 - $35.99 $69,693 - $85,548
2,377 Added 18.48%
15,241 $486,000
Q1 2023

May 11, 2023

BUY
$30.15 - $48.79 $158,106 - $255,854
5,244 Added 68.82%
12,864 $393,000
Q4 2022

Feb 07, 2023

BUY
$36.73 - $51.6 $74,929 - $105,264
2,040 Added 36.56%
7,620 $298,000
Q3 2022

Nov 10, 2022

BUY
$39.79 - $70.31 $222,028 - $392,329
5,580 New
5,580 $266,000
Q2 2022

Aug 03, 2022

SELL
$29.86 - $62.36 $106,062 - $221,502
-3,552 Closed
0 $0
Q1 2022

May 04, 2022

BUY
$53.73 - $82.16 $190,848 - $291,832
3,552 New
3,552 $204,000
Q4 2021

Feb 04, 2022

SELL
$68.02 - $99.06 $336,699 - $490,347
-4,950 Closed
0 $0
Q3 2021

Oct 07, 2021

BUY
$84.37 - $133.6 $417,631 - $661,320
4,950 New
4,950 $431,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.7B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.